| Nov 19 |
The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate.
|
| Nov 14 |
Annexon Biosciences GAAP EPS of -$0.25 beats by $0.03
|
| Nov 14 |
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
|
| Nov 13 |
Annexon Biosciences to Present at the Jefferies London Healthcare Conference
|
| Oct 22 |
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
|
| Oct 21 |
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
|
| Oct 15 |
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
|
| Sep 9 |
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress
|
| Sep 3 |
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
|
| Aug 29 |
Annexon Biosciences to Participate in Upcoming September Investor Conferences
|
